Parexel News (NASDAQ:PRXL)

DateTimeSource
Headline
06/26/20179:00AMBWPAREXEL Named to the Forbes America’s Best Employers List for Second Consecutive Year
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that for the second year in a row, Forbes has named the Company to its America’s “Best Employers” list. The list recognizes the top 300 midsized employers and top 500 large employers. Results... More...>>
06/20/20175:44PMPRNUSHarwood Feffer LLP Announces Investigation of PAREXEL International Corporation
Harwood Feffer LLP Announces Investigation of PAREXEL International Corporation PR Newswire NEW YORK, June 20, 2017 NEW YORK, June 20, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of PAREXEL International Corporation ("PAREXEL" or the "Company... More...>>
06/20/20179:49AMDJNHot Stocks to Watch in the U.S. and Canada
Among the companies with shares expected to trade actively in Tuesday's session are Parexel International Corp. (PRXL), Boeing Co. (BA), Apple Inc. (AAPL), and Lipocine Inc. (LPCN). Private-equity firm Pamplona Capital Management reached a deal to buy Parexel for $4.6 billion, the latest in a series of mergers among... More...>>
06/20/20177:05AMBWPAREXEL International Enters Definitive Agreement to Be Acquired by Pamplona Capital Management for $88.10 Per Share in Cash
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Pamplona Capital Management, LLP (Pamplona) today announced that they have entered into a definitive agreement under which Pamplona will acquire all of the outstanding shares of PAREXEL for $88.10 per share in cash... More...>>
06/19/20178:00AMBWPAREXEL Introduces Its Connected Journey™ of Newly Integrated Data-Driven Services to Simplify Drug Development & Commercia...
Features new ForeSite™ clinical trial methodology designed to reliably predict site success As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical... More...>>
06/19/20177:30AMBWPAREXEL’s Alberto Grignolo Named Fellow by Drug Information Association
Honored for contributing to the advancement of health care PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Alberto Grignolo, Ph.D., Corporate Vice President, PAREXEL Consulting, has been named a Fellow by the Drug Information Association (DIA... More...>>
06/15/20178:00AMBWPAREXEL Collaborates with Sanofi to Advance the Use of Wearable Devices in Life Science Industry
Preliminary findings from pilot study validate use of wearable technologies to collect data and manage clinical trials more effectively and efficiently PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced a collaboration with Sanofi to advance the use... More...>>
06/12/20174:01PMBWPAREXEL Experts to Discuss Key Drug Development Insights at DIA 2017
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that several of its experts will discuss key issues facing the industry at the 53rd Drug Information Association (DIA) Annual meeting, held from June 18 to 22, 2017 in Chicago. PAREXEL will hold in-booth... More...>>
06/09/20176:50AMPRNUSHealthcare Stocks on Investors' Radar -- PAREXEL, IDEXX Labs, ICON PLC, and PRA Health Sciences
Healthcare Stocks on Investors' Radar -- PAREXEL, IDEXX Labs, ICON PLC, and PRA Health Sciences PR Newswire NEW YORK, June 9, 2017 NEW YORK, June 9, 2017 /PRNewswire/ -- On Thursday, June 08, 2017, US markets saw a mixed session as 4 sectors closed in green, 3 sectors finished in red, and 2 sectors ended flat for the day... More...>>
05/03/20174:42PMBWPAREXEL International Reports Third Quarter Fiscal Year 2017 Results
Service revenue of $529.3 million, GAAP diluted EPS of $0.35; adjusted diluted EPS of $0.74 Company adopts new policy for reporting new business and backlog to align with emerging industry norm Net new business of $648 million, net book-to-bill ratio of 1.22, backlog of $4.06 billion on the new basis Restructuring program... More...>>
04/17/20179:00AMBWParexel International Announces Date of Third Quarter Fiscal Year 2017 Earnings Release and Conference Call
PAREXEL International Corporation (NASDAQ: PRXL) will release financial results for the Third Quarter Fiscal Year 2017 on Wednesday, May 3, 2017 after the close of the stock market. PAREXEL will host a conference call and live webcast at 10:00 a.m. ET on Thursday, May 4, 2017 to discuss the results. To access the webcast... More...>>
04/03/20179:00AMBWPAREXEL Ranked a Top CRO in CenterWatch Global Investigative Site Relationship Survey
Company recognized for sponsor/site relationship quality PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that it was named a top contract research organization (CRO) in the CenterWatch 2017 Global Investigative Site Relationship Survey. The survey... More...>>
03/30/20179:00AMBWPAREXEL Launches Patient Sensor Solution to Transform Clinical Trial Data Collection
Comprehensive wearables and sensors solution, powered by the Perceptive MyTrials® Analytics platform, creates greater efficiencies for biopharmaceutical companies PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of its patient sensor solution... More...>>
03/13/20179:00AMBWPAREXEL Named a FlexJobs Top 100 Company to Watch for Telecommuting and Remote Jobs in 2017
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that it has been named to the FlexJobs Top 100 Companies to Watch for Telecommuting and Remote Jobs in 2017 list for the fourth consecutive year. The list recognizes companies that are telecommuting-friendly... More...>>
02/28/20177:00AMBWPAREXEL International Appoints Simon Harford as Senior Vice President and Chief Financial Officer
Appointment Effective June 1, 2017 PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of Simon Harford as Senior Vice President and Chief Financial Officer effective June 1, 2017. He will serve on PAREXEL's Business Review Committee, the... More...>>
02/22/201710:00AMBWPAREXEL International to Participate at Cowen & Co. Health Care Conference and Barclays Global Healthcare Conference
PAREXEL International Corporation (NASDAQ: PRXL) announced today that executives will be participating at two investor conferences in March. Emma Reeve, Corporate Vice President and Interim Chief Financial Officer, will meet with investors at the Cowen and Company Health Care Conference on Monday, March 6, 2017, in Boston... More...>>
02/13/20179:00AMBWPAREXEL Launches ClinPhone RTSM Mobile App to Improve Supply Management and Increase Patient Safety
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched a mobile app for the ClinPhone® RTSM (randomization and trial supply management) service. The app is designed to enhance clinical trial supply management processes, increase patient safety, and improve... More...>>
02/09/20174:05PMGLOBEQuotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer
JERSEY, Channel Islands, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Christopher Lindop as Chief Financial Officer.  Mr. Lindop will commence his new role on February 15, 2017. Mr. Lindop joins Quotient with more... More...>>
02/07/20171:00PMBWPAREXEL International to Present at Leerink Partners Healthcare Conference
PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Leerink Partners Healthcare Conference on Thursday, February 16, 2017, in New York City. Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a presentation on PAREXEL and discussing business developments... More...>>
02/01/201711:18PMBWPAREXEL International Reports Second Quarter Fiscal Year 2017 Results
Second Quarter Fiscal Year 2017 Results (compared to Second Quarter Fiscal Year 2016) Service revenue of $534.4 million, up 3.1% GAAP diluted earnings per share of $0.41, down 43.8%; adjusted earnings per share of $0.85, down 5.6% Gross new business of $971 million, cancellations of $266 million Backlog increased 8.4... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20170629 05:27:55